Trifluorothymidine
Trifluorothymidine structure
|
Common Name | Trifluorothymidine | ||
|---|---|---|---|---|
| CAS Number | 70-00-8 | Molecular Weight | 296.200 | |
| Density | 1.6±0.1 g/cm3 | Boiling Point | N/A | |
| Molecular Formula | C10H11F3N2O5 | Melting Point | 190-193 °C(lit.) | |
| MSDS | Chinese USA | Flash Point | N/A | |
| Symbol |
GHS07, GHS08 |
Signal Word | Warning | |
|
Mechanistic evaluation of Ginkgo biloba leaf extract-induced genotoxicity in L5178Y cells.
Toxicol. Sci. 139(2) , 338-49, (2014) Ginkgo biloba has been used for many thousand years as a traditional herbal remedy and its extract has been consumed for many decades as a dietary supplement. Ginkgo biloba leaf extract is a complex mixture with many constituents, including flavonol glycoside... |
|
|
Quantitative high-throughput identification of drugs as modulators of human constitutive androstane receptor.
Sci. Rep. 5 , 10405, (2015) The constitutive androstane receptor (CAR, NR1I3) plays a key role in governing the transcription of numerous hepatic genes that involve xenobiotic metabolism/clearance, energy homeostasis, and cell proliferation. Thus, identification of novel human CAR (hCAR... |
|
|
Differential activation of cell death and autophagy results in an increased cytotoxic potential for trifluorothymidine compared to 5-fluorouracil in colon cancer cells.
Int. J. Cancer 126 , 2457-2468, (2010) Trifluorothymidine (TFT) is part of the oral drug formulation TAS-102. Both 5-fluorouracil (5-FU) and TFT can inhibit thymidylate synthase and be incorporated into DNA. TFT shows only moderate cross-resistance to 5-FU. Therefore, we examined whether mechanist... |
|
|
Trifluorothymidine resistance is associated with decreased thymidine kinase and equilibrative nucleoside transporter expression or increased secretory phospholipase A2.
Mol. Cancer Ther. 9 , 1047-1057, (2010) Trifluorothymidine (TFT) is part of the novel oral formulation TAS-102, which is currently evaluated in phase II studies. Drug resistance is an important limitation of cancer therapy. The aim of the present study was to induce resistance to TFT in H630 colon ... |
|
|
Trifluorothymidine induces cell death independently of p53.
Nucleosides Nucleotides Nucleic Acids 27 , 699-703, (2008) Trifluorothymidine (TFT), a potent anticancer agent, inhibits thymidylate synthase (TS) and is incorporated into the DNA, both events resulting in cell death. Cell death induction related to DNA damage often involves activation of p53. We determined the role ... |
|
|
Mode of action of trifluorothymidine (TFT) against DNA replication and repair enzymes.
Int. J. Oncol. 39 , 263-270, (2011) Trifluorothymidine (TFT) is well known to be converted to TFT-monophosphate by thymidine kinase and to inhibit thymidylate synthase. In addition, TFT-triphosphate (TFT-TP) is also incorporated into DNA, resulting in cytocidal effects. However, the precise mec... |
|
|
Simple and rapid enzymatic method for the synthesis of single-strand oligonucleotides containing trifluorothymidine.
Nucleosides Nucleotides Nucleic Acids 29 , 896-904, (2010) To investigate the mechanism of trifluorothymidine (TFT)-induced DNA damage, we developed an enzymatic method for the synthesis of single-strand oligonucleotides containing TFT-monophosphate residues. Sixteen-mer oligonucleotides and 14-mer 5'-phosphorylated ... |
|
|
Novel cell death mechanisms of trifluorothymidine. Bijnsdorp IV, Kruyt F, et al.
Nucleic Acids Symp. Ser. 52 , 649, (2008)
|